SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
INBX reported Third Quarter 2026 results. The stock moved -6.8% on the print.
INBXearnings

Earnings reactions, page 2

Inhibrx Biosciences, Inc. (INBX) Q3 FY2026 earnings

November 14, 2026 · SharpeIQ Research Desk

Reported results

  • Recognized $2.0 million of license fee revenue during the third quarter of 2026, compared to $0 in the third quarter of 2025.
  • Research and development expenses were $26.0 million for the third quarter of 2026, compared to $28.5 million for the third quarter of 2025.
  • General and administrative expenses were $7.8 million during the third quarter of 2026, compared to $5.3 million during the third quarter of 2025.
  • Total other expense was $7.0 million during the third quarter of 2026, compared to $1.4 million during the third quarter of 2025.
  • Net loss was $38.7 million, or $2.46 per basic and diluted share, during the third quarter of 2026, compared to a net loss of $35.3 million, or $2.28 per basic and diluted share, during the third quarter of 2025.
  • Cash and cash equivalents were $199.5 million as of September 30, 2026.

Price and volatility reaction

The stock moved -6.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +11.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release83.32026-11-13
Close after release77.662026-11-16
Realised move-6.8%close to close
30d ATM IV change+11.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →